-
《A urine‑based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer》发表于《Clinical Epigenetics》(影响因子6.551)
基准医疗与中山|kaiyun开云平台China官方网站大学孙逸仙纪念医院林天歆及黄健课题组在《Clinical Epigenetics》(影响因子7.259)发表《A urine‑based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer》
-
“钟声计划”的相关临床研究文章发表于国际领先学术期刊《Translational Lung Cancer Research》(影响因子5.132)
基准医疗与国家呼吸医学中心钟南山院士团队,联合国内23家顶级医院开展的“钟声计划—ctDNA甲基化高通量检测用于肺部结节良恶性诊断和监测的临床研究(NCT03651986)”项目成果发表在国际领先学术期刊《Translational Lung Cancer Research》(影响因子4.726)
-
《Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer》发表于国际知名学术期刊JCI(影响因子:19.456)
基准医疗与与中山|kaiyun开云平台China官方网站大学孙逸仙纪念医院林天歆及黄健课题组在国际知名学术期刊《The Journal of Clinical Investigation》(影响因子:19.456)发表了 《Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer》的临床研究论文。
-
《Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA)》发表于《Theranostics》 (影响因子:8.579)
基准医疗与广州医科|kaiyun开云平台China官方网站大学附属第一医院何建行教授/梁文华教授团队在《Theranostics》(影响因子:11.600)发表了 《Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA)》的文章。